Why is Biogen Pharma falling/rising?

As of 18-Sep, Biogen Pharmachem Industries Ltd is experiencing a decline in its stock price, currently at 0.89, which reflects a decrease of 0.01 or 1.11%. The stock has underperformed its sector by 0.35% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has also shown a negative return of 1.11%, while its year-to-date performance is down by 24.58%. Despite declaring positive results for the last two consecutive quarters, including the highest PBDIT, PBT, and PAT at Rs 1.34 crore, the stock's weak long-term fundamental strength is concerning, as indicated by an average Return on Equity (ROE) of just 2.43% and a poor EBIT to Interest ratio of 1.19.
In the broader market context, Biogen's recent performance contrasts sharply with the Sensex, which has gained 1.80% over the past week and 6.24% year-to-date. This disparity highlights the stock's struggles relative to the overall market. The company's valuation appears expensive with a Price to Book Value of 1.4, and despite trading at a discount compared to its peers, it has generated a significant negative return of 31.54% over the past year, alongside a profit decline of 11%. This combination of underperformance and weak financial metrics contributes to the stock's downward movement.